ArticleJournal of endocrinological investigation2025
Dapagliflozin ameliorates high glucose-induced epithelial-mesenchymal transition via up-regulating ACE2 mediated by EZH2 in diabetic nephropathy.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Significance and Potential Molecular Mechanisms of Angiotensin-Converting Enzyme 2 in Colorectal Cancer.World journal of oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the protective function and underlying mechanism of dapagliflozin on tubulointerstitial fibrosis (TIF) in diabetic nephropathy (DN).
methodsIn this study, we constructed the high-fat and high-glucose diet combined with streptozocin (STZ)-induced DN rat model and 0.2 mg/kg/d of dapagliflozin pretreatment model. After the experiment, kidney tissues were retained for subsequent experiments. In vitro, human renal tubular epithelial cells were treated with different concentrations of glucose and dapagliflozin to investigate the reno-protective functions and potential mechanisms of dapagliflozin in DN.
resultsOur study revealed that dapagliflozin could significantly inhibit epithelial-mesenchymal transition (EMT) and TIF. Meanwhile, dapagliflozin improved cytoskeleton rearrangement and cellular migration capacity. Also, dapagliflozin restored the expression of angiotensin-converting enzyme 2 (ACE2) in human proximal tubular epithelial cells (HK2) and DN rats. Rescue experiments additionally demonstrated that the effects of dapagliflozin were attenuated by blocking ACE2 with MLN-4760, an ACE2 inhibitor, and by siRNA knockdown of ACE2 in HK2 cells. In addition, MLN-4760 and si-ACE2 reversed the decreased pro-fibrotic cytokine TGF-β1 induced by dapagliflozin. Further, results showed that dapagliflozin could inhibit EZH2 and H3K27me3 expression. H3K27me3 partially co-localized with ACE2 and their expression was negatively correlated. Following the over-expression of EZH2, there was a significant up-regulation of H3K27me3 in HK2 cells, then the high expression of ACE2 induced by dapagliflozin was significantly inhibited.
conclusionsDapagliflozin could up-regulate ACE2 by inhibiting EZH2-mediated ACE2 histone methylation, further exerting anti-fibrotic effects by inhibiting downstream activation of TGF-β1.
Indexed as
Identifiers
40658352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.